Intellia says FDA accepts lonvo-z BLA for hereditary angioedema, grants priority review
NTLA•FDA accepts lonvo-z application with priority review
- FDA accepted Intellia’s BLA for lonvoguran ziclumeran (lonvo-z) in hereditary angioedema, granting Priority Review.
- PDUFA target action date set for March 10, 2027.
- FDA does not currently plan to convene an advisory committee for the application.
Related News
Xerox shareholder pushing co to take action to unlock shareholder value, asking for strategic review of its financial services business
XRX•
Orion Energy wins additional multimillion-dollar LED lighting order from global hyperscaler
OESX•
